3/8/2010 | CV | Enzon gets no tenders of 4% convertibles; $115.6 million converted
|
2/5/2010 | CV | Enzon launches cash tender offer for its 4% convertible notes due 2013
|
1/29/2010 | CV | Enzon to tender for its 4% convertibles with proceeds from asset sale
|
12/14/2009 | SS | Enzon shareholder DellaCamera seeks to declassify company's board
|
11/10/2009 | CV | Enzon asset sale should trigger put option for 4% convertibles, Bank of America Merrill Lynch says
|
11/9/2009 | CV | Market Commentary: Ford convertibles regain some ground; Enzon active; Freeport-McMoRan adds; More supply ahead
|
11/9/2009 | SS | Enzon to sell specialty pharmaceutical business to Italian company
|
11/9/2009 | SS | Market Commentary: Kraft sticks to Cadbury bid; Cisco extends Tandberg offer; Enzon may use deal to redeem debt
|
7/23/2009 | SS | Enzon splits role of CEO, chairman and adds new director to board
|
7/21/2009 | SS | Enzon sets July 24 record date for DellaCamera's consent solicitation
|
7/7/2009 | SS | Enzon shareholder requests company set record date for consent action
|
6/17/2009 | SS | Enzon shareholder preps for solicitation to remove company's CEO
|
5/7/2009 | CV | Enzon records $4.5 million gain on repurchase of convertible notes during first quarter
|
5/7/2009 | SS | Enzon's motion for expedited proceedings in DellaCamera action denied
|
4/28/2009 | SS | Enzon shareholder DellaCamera opposed to company's filing of lawsuit
|
4/23/2009 | SS | Enzon defends performance of CEO ahead of battle with DellaCamera
|
4/22/2009 | SS | Enzon shareholder DellaCamera wants to oust company's CEO/president
|
3/2/2009 | SS | Enzon shareholder DellaCamera continues to push for answers
|
2/19/2009 | CV | Enzon to hold off on further convertibles buybacks until discounts widen
|
2/19/2009 | CV | Enzon buys back $76.9 million of convertibles in 2008
|
2/19/2009 | SS | Market Commentary: Dow falls to 2002 watermark; Enzon spinoff stuck on back burner; Whole Foods' stock on the move
|
2/17/2009 | SS | Enzon Pharmaceuticals shareholder seeks answers to specific questions on Thursday
|
2/10/2009 | SS | DellaCamera demands Enzon name two to board, asks company to take responsibility for failures
|
1/30/2009 | SS | Enzon shareholders question management, seek 'legitimate' auction for entire company
|
1/28/2009 | SS | DellaCamera pushes Enzon to explore strategic alternatives
|
1/22/2009 | CV | Market Commentary: Convertibles mixed as activity picks up; Massey Energy trades; Alliant Techsystems comes off slightly
|
1/21/2009 | CV | Enzon holders tender mere fraction of 4% convertibles in Dutch auction tender offer
|
1/8/2009 | CV | Market Commentary: Convertibles trade mixed: Qwest gains with shares, but AMD sags; Enzon adds on extended tender
|
1/8/2009 | CV | Enzon Pharmaceuticals extends partial Dutch auction tender offer for 4% convertibles
|
12/8/2008 | CV | Enzon Pharmaceuticals begins partial Dutch auction tender offer for 4% convertibles
|
12/5/2008 | CV | Market Commentary: Nabors little changed on lower oil; GM, Ford mixed; Sinclair Broadcast for sale, but no buyers seen
|
12/4/2008 | CV | Market Commentary: Prudential longer paper gains; ImClone weaker; Advanced Micro mostly quiet on lowered outlook
|
12/3/2008 | CV | Enzon Pharmaceuticals board OKs modified Dutch auction tender for 4% convertibles
|
12/1/2008 | SS | Enzon Pharmaceuticals won't spin off biotech business
|
11/26/2008 | SS | Enzon investor DellaCamera questions planned spinoff of biotech business
|
11/19/2008 | SS | DellaCamera reports 7.8% stake in Enzon Pharmaceuticals
|
11/6/2008 | CV | Market Commentary: Convertibles softer; General Growth wallows in the teens, Enzon lower; Carrizo down outright
|
10/7/2008 | SS | DellaCamera buys more Enzon shares, believes stock is undervalued
|
8/25/2008 | CV | Enzon Pharmaceuticals gets consents needed to amend 4% convertibles
|
8/13/2008 | CV | Enzon Pharmaceuticals seeks consents for its 4% convertibles due 2013
|
7/1/2008 | SS | DellaCamera suggests ways for Enzon Pharmaceuticals to increase value for stockholders
|
5/20/2008 | SS | DellaCamera says Enzon needs to do more than spin off its biotech business
|
5/7/2008 | SS | Market Commentary: Sprint, Clearwire cross lines; pilots call U.S. Air, UAL deal 'last resort'; Microsoft, Yahoo! carry on alone
|
5/7/2008 | CV | Market Commentary: Legg Mason, Synnex up on debut; Enzon slips on spin-off; Fannie Mae quiet; Transocean, Cheniere gain
|
5/7/2008 | CV | Enzon repurchases $59.9 million of its 2008 convertibles
|
5/7/2008 | SS | Enzon Pharmaceuticals to spin off biotechnology business
|
5/1/2008 | SS | DellaCamera asks for Enzon Pharmaceuticals directors to resign, gives board a vote of no confidence
|
3/14/2008 | SS | Icahn ups stake in Enzon, wants company to consider sale
|
2/12/2008 | SS | Enzon to add independent board member under agreement with DellaCamera
|
1/14/2008 | SS | DellaCamera Capital seeks representation on Enzon Pharmaceutical's board
|
12/19/2007 | SS | Enzon investor wants company to retain financial adviser, consider alternatives
|
8/20/2007 | CV | Enzon to retire 4.5% convertibles
|
11/2/2006 | BT | Enzon ends third quarter in the black, with $170 million of cash
|
8/1/2006 | BT | Enzon tests Oncaspar, Gemzar in solid tumors, lymphomas
|
8/1/2006 | BT | Enzon reports $11.0 million second quarter net income; starts Oncaspar phase 1 clinical trial
|
7/27/2006 | BT | Enzon, Santaris to develop RNA antagonists for cancer therapeutics
|
7/27/2006 | BT | Cambridge Antibody acquires Enzon oncology product
|
7/25/2006 | BT | Enzon's leukemia drug Oncaspar gets FDA approval
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/6/2006 | BTCV | Enzon Pharmaceuticals gets tenders for $137.581 million 4.5% convertibles due 2009
|
6/6/2006 | BTCV | Enzon Pharmaceuticals tenders for 4.5% convertibles due 2009
|
6/1/2006 | BTCV | Enzon greenshoe exercised, lifting 4% convertibles issue to $275 million
|
5/18/2006 | CV | Market Commentary: Enzon climbs, Nabors flat on debuts; American Axle gains on conversion expectations; DOV slides further
|
5/18/2006 | BTCV | New Issue: Enzon prices upsized $225 million seven-year convertibles at cheap end of talk, at 4%, up 25%
|
5/17/2006 | CV | Market Commentary: American Axle continues rally on conversion option; Greenbrier up on debut; Enzon deal seen as decent
|
5/16/2006 | BTCV | Enzon $175 million seven-year convertibles talked at 3.5%-4%, up 25%-30%
|
5/16/2006 | BTCV | Enzon Pharmaceuticals plans to buy back 4.5% convertibles
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
4/3/2006 | BT | Enzon plans to start enrollment in trials of Oncaspar as FDA completes review
|
1/6/2006 | BT | Enzon returns rights to transplantation product to Fresenius Biotech
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/10/2005 | BT | Enzon says FDA approves intravenous Oncaspar for pediatric leukemia
|
10/31/2005 | BT | Enzon reduces royalty payments to Sanofi-Aventis for oncology treatment Oncaspar
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
2/24/2005 | CV | Market Commentary: Genesis finds bid; UniSource goes past 102; Calpine bonds fall, then bounce back while preferreds gain
|
9/17/2004 | CV | Market Commentary: Sepracor issue straddles par; Vitesse goes to 103; EDS firm despite warning; biotechs rally
|
2/20/2003 | CV | Market Commentary: Williams boosts entire slate of power names; FCC ruling sends telecoms tumbling
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
5/15/2002 | CV | Market Commentary: Pep Boys advances pricing; market run ends in thud
|